StockData
Incannex Healthcare Inc. logo

Incannex Healthcare Inc. (IXHL) stock

IXHLNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$1.74−0.19 (-9.84%)

Close on Nov 17, 2026Market cap $21.83MP/E –Yield –

Incannex Healthcare r&d expenses

Research and development expenses are spending on new products and technology.

Incannex Healthcare's R&D Expenses for the twelve months ending Sep 30, 2026 was $5.21M, down 41.9% year over year. For fiscal 2026 it was $5.21M, down 51.5% from the year before. The highest annual figure on record is $12.88M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Jun 30, 2026$5.21M-51.5%
FY2025Jun 30, 2025$10.75M-16.6%
FY2024Jun 30, 2024$12.88M+104.1%
FY2023Jun 30, 2023$6.31M+17.4%
FY2022Jun 30, 2022$5.37M+13.1%
FY2021Jun 30, 2021$4.75M+125.0%
FY2020Jun 30, 2020$2.11M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ3 2026Sep 30, 2026$1.12M+0.3%
Q4 FY2026CQ2 2026Jun 30, 2026$1.49M-59.8%
Q3 FY2026CQ1 2026Mar 31, 2026$321.00K-88.3%
Q2 FY2026CQ4 2025Dec 31, 2025$2.28M+61.2%
Q1 FY2026CQ3 2025Sep 30, 2025$1.12M-61.3%
Q4 FY2025CQ2 2025Jun 30, 2025$3.70M-15.1%
Q3 FY2025CQ1 2025Mar 31, 2025$2.74M-16.5%
Q2 FY2025CQ4 2024Dec 31, 2024$1.41M-46.4%
Q1 FY2025CQ3 2024Sep 30, 2024$2.90M+11.0%
Q4 FY2024CQ2 2024Jun 30, 2024$4.36M+154.6%
Q3 FY2024CQ1 2024Mar 31, 2024$3.28M+99.9%
Q2 FY2024CQ4 2023Dec 31, 2023$2.64M+70.3%
Q1 FY2024CQ3 2023Sep 30, 2023$2.61M–
Q4 FY2023CQ2 2023Jun 30, 2023$1.71M–
Q3 FY2023CQ1 2023Mar 31, 2023$1.64M–
Q2 FY2023CQ4 2022Dec 31, 2022$1.55M–

More Incannex Healthcare figures

See a number that looks wrong?